marinedrugs Marine Drugs Mar. Drugs Marine Drugs 1660-3397 MDPI 10.3390/md10112535 marinedrugs-10-02535 Review Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids Russell Fraser D. * Bürgin-Maunder Corinna S. Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Maroochydore, Queensland 4556, Australia; Email: CBurgin@usc.edu.au Author to whom correspondence should be addressed; Email: frussell@usc.edu.au; Tel.: +61-7-5459-4665. 13 11 2012 11 2012 10 11 2535 2559 24 09 2012 16 10 2012 31 10 2012 © 2012 by the authors; licensee MDPI, Basel, Switzerland. 2012

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) are recommended for management of patients with wide-ranging chronic diseases, including coronary heart disease, rheumatoid arthritis, dementia, and depression. Increased consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is recommended by many health authorities to prevent (up to 0.5 g/day) or treat chronic disease (1.0 g/day for coronary heart disease; 1.2–4 g/day for elevated triglyceride levels). Recommendations for dietary intake of LC n-3 PUFAs are often provided for α-linolenic acid, and for the combination of EPA and DHA. However, many studies have also reported differential effects of EPA, DHA and their metabolites in the clinic and at the laboratory bench. The aim of this article is to review studies that have identified divergent responses to EPA and DHA, and to explore reasons for these differences. In particular, we review potential contributing factors such as differential membrane incorporation, modulation of gene expression, activation of signaling pathways and metabolite formation. We suggest that there may be future opportunity to refine recommendations for intake of individual LC n-3 PUFAs.

 LC n-3 PUFAs omega-3 fatty acids eicosapentaenoic acid docosahexaenoic acid resolvin D1 differential response omega-3 fatty acid metabolites 1. Recommendations for Daily Intake of <italic>n</italic>-3 PUFAs

Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) are fatty acids with a long chain (20 carbons or more), with the first double bond located after the third carbon from the methyl end. LC n-3 PUFAs, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have long been proposed to bestow health benefits by improving blood pressure control, alleviating symptoms of rheumatoid arthritis and depression, as well as attenuating the progression of Alzheimer’s disease [1,2,3,4]. It is noteworthy that recent meta-analyses have reported no effect of LC n-3 PUFAs on incidence of fatal coronary heart disease and sudden death [5,6], in stark contrast to earlier trials that reported marked reductions in risk for these events [7,8]. Differences in trial design (open label versus randomized, double-blind, placebo controlled), baseline clinical management (for example, low versus high use of anti-thrombotic and anti-hypertensive medications), and absolute risk for adverse events (for example, patients with few versus many risk factors, including previous myocardial infarction, with diabetes and low use of statins), have been postulated to explain the divergent findings [9]. Dose is also an important determinant of patient outcome, where high doses only of LC n-3 PUFAs (for example, 2–4 g EPA + DHA/day) can provide cardiovascular benefit associated with serum triglyceride reduction [10]. Whilst evidence for the capacity of LC n-3 PUFAs to lower serum triglyceride concentration is particularly strong, improvements in patient outcome have additionally been ascribed to modulation of signaling pathways involved in inflammation and oxidative stress, improvement in endothelial function, and inhibition of platelet aggregation (see Section 2).

Although plant-derived α-linolenic acid (ALA) is obtained from dairy products and margarines [11] and can be enzymatically converted to EPA and DHA in humans, the process is inefficient (0.04%–2.84%), and restricted by high dietary intake of EPA, DHA and linoleic acid [12,13]. Whilst low delta-6 desaturase activity in humans contributes to poor conversion of ALA to EPA and DHA [14], levels of EPA and DHA can nonetheless be increased through dietary intake of LC n-3 PUFA-enriched foods or marine oil supplements containing these fatty acids [15]. Major sources of LC n-3 PUFAs in the diet of developed countries are fish, red meat and poultry [11,16,17], where combinations of these foods contribute high levels (>75% of the total intake derived from 29 different food groups) of DHA (fish and poultry), EPA (fish and red meat), and docosapentaenoic acid (DPA; red meat, poultry and fish) [11]. Many of the aforementioned benefits of LC n-3 PUFAs have been attributed to the intake of DHA and/or EPA.

Countries that have high dietary intake of fish, such as Japan, have populations that benefit from cardioprotective levels of LC n-3 PUFAs [18]. However, many populations consume amounts of LC n-3 PUFAs that are regarded as “adequate”, avoiding problems associated with deficiency, but not enough to provide health protection. Health authorities in these countries recommend increased intake of LC n-3 PUFAs to provide such benefits. For example, European health authorities recommend at least 0.45–0.50 g/day EPA + DHA to maintain good health [19,20,21]. The mean daily intake of EPA + DHA and ALA in Australian adults is 0.175 g and 1.07 g, respectively [22]. The Heart Foundation of Australia recommends a daily dietary intake of 0.5 g EPA + DHA plus 2.0 g ALA to lower the risk of coronary heart disease, 1.0 g EPA + DHA plus 2.0 g ALA for patients with documented coronary heart disease, and 1.2–4.0 g EPA + DHA for patients with elevated serum triglyceride levels [22]. Table 1 collates recommendations for dietary intake of LC n-3 PUFAs by selected National and International health and government organizations. Most of these organizations have issued recommendations for combined intake of EPA and DHA, but do not provide advice for the ratio of EPA to DHA. The French Agency for Food, Environmental and Occupational Health & Safety [20] is a notable exception, providing separate recommendations for dietary intake of EPA and DHA (Table 1). Following the American Psychiatric Association recommendation of 1.0 g/day DHA+EPA for the treatment of affective disorders ([23], Table 1), McNamara [24] proposed a 2:1 ratio of EPA:DHA for optimal patient management.

Differential associations for cell membrane EPA and DHA levels and resting state electroencephalographic (EEG) activity have been reported. DHA was associated with fast frequency EEG activity while EPA was associated with slow frequency EEG activity in 46 adolescent boys with attention deficit hyperactivity disorder [25]. Not surprisingly, the health benefits of the LC-n-3 PUFAs have often been ascribed to particular types of LC-n-3 PUFAs. For example, studies have reported blood pressure lowering effects of DHA but not EPA [26,27], while EPA has been reported to be more efficacious than DHA in reducing platelet activation [28,29]. The differential response to EPA and DHA suggests that an opportunity might exist to customize advice for the types or ratios of LC n-3 PUFAs to be used in the treatment of particular conditions or diseases. The implementation of such a strategy is certainly achievable, with a plethora of commercially available dietary marine oil supplements of defined LC n-3 PUFA composition [30]. For example, EPAX 5510 TG/N is an EPA-rich oil (EPA/DHA ratio of 5:1), while EPAX 1050 TG/N is a DHA-rich oil (EPA/DHA ratio of 1:5) [31]. Salunkhe et al. [32] recently identified a marine bacterial isolate that produces high concentrations of EPA (60% of total fatty acid content) at 30 °C, with no detectable production of DHA. The strategy may also be achievable by considering the dietary intake of fish and meat sources. For example, of fish high in LC n-3 PUFAs content, the ratio of EPA:DHA can range from ~1:2 for Atlantic Salmon and Ocean Trout to ~1:30 for Snook [33].

The purpose of this review is to examine studies that have reported heterogeneity with respect to effects of the LC n-3 PUFAs, chiefly EPA and DHA, and to examine some of the reasons for these differential responses. In particular, we review the impact of differential metabolism, membrane incorporation, modulation of gene expression, and activation of signaling pathways for EPA and DHA.

marinedrugs-10-02535-t001_Table 1

Recommendations for Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) intake obtained from selected national and international health and government organizations.

Health Organization Country Recommendation Ref.
National Heart Foundation Australia 0.5 g/day EPA + DHA plus 2 g/day ALA to lower the risk of coronary heart disease; 1.0 g/day EPA + DHA plus 2 g/day ALA for patients with documented coronary heart disease; 1.2–4.0 g/day EPA + DHA for patients with elevated serum triglyceride levels. [22]
American Heart Association USA ≥2 fish meals/week plus oils rich in ALA in subjects without coronary heart disease; 1.0 g/day EPA + DHA for patients with documented coronary heart disease; 2.0–4.0 g/day EPA + DHA for patients with elevated serum triglyceride levels. [34]
World Health Organization International 0.2–0.5 g/day EPA+DHA to prevent coronary heart disease and ischemic stroke. [35]
American Psychiatric Association USA 1.0 g/day EPA + DHA for treatment of affective disorders. [23]
1. National Health and Medical Research Council. 2. The Cancer Council Australia. 1. Australia & New Zealand.2. Australia Adequate Intake for EPA + DHA + DPA: 0.09 g/day (women ≥ 19 years), 0.16 g/day (men ≥ 19 years). ALA: 0.8 g/day (women ≥ 19 years), 1.3 g/day (men ≥ 19 years). Intake of EPA + DHA + DPA to reduce risk of chronic disease: 0.43 g/day (women), 0.61 g/day (men). [36,37]
Scientific Advisory Committee on Nutrition UK General nutrition, at least 0.45 g/day LC n-3 PUFAs. [19]
French Agency for Food, Environmental and Occupational Health & Safety France General nutrition, 0.25 g/day EPA; 0.25 g/day DHA, 1% of energy intake ALA. [20]
Health Council of the Netherlands Netherlands General nutrition, 0.45 g/day fish fatty acids. [21]
International Society for the Study of Fatty Acids and Lipids International Cardiovascular health, ≥0.5 g/day EPA + DHA. General nutrition, 0.7% of energy intake ALA. [38]
2. Evidence for Differential Responses to EPA and DHA

Although EPA and DHA are both long chain polyunsaturated fatty acids (EPA, C20:5n3; DHA, C22:6n3), the molecules are often reported to produce biochemical and physiological responses that are qualitatively and quantitatively different to each other. Table 2 provides a non-exhaustive overview of studies that report differential effects of EPA and DHA, and their metabolites. Each individual study represented in Table 2 was internally controlled, thus allowing direct comparisons of responses to the fatty acids under identical experimental conditions. This is an important point, since differences in experimental design between studies have sometimes led to inconsistent conclusions in regard to the effects of the LC n-3 PUFAs. When considering the blood pressure lowering effects of LC n-3 PUFAs for example, the reader needs to be cognisant of the effects of dose and duration of treatment, baseline characteristics of the subject for dietary intake of LC n-3 PUFAs and blood pressure, subject age, co-morbidities, and use of anti-hypertensive medications. It is nonetheless noteworthy that several studies in Table 2 reported response, and/or lack of response that was based on the examination of a single concentration of the LC n-3 PUFAs. In those studies it is possible that information obtained from construction of full dose-response curves to EPA and DHA might have shown the same qualitative response, albeit with different potencies and/or efficacies. For example, Yusufi et al. [39] reported an inhibitory effect of low concentration (10 μM) DHA, but not EPA on EGF-stimulated mitogenesis in mesangial cells. However, an inhibitory effect of EPA, quantitatively similar to that of DHA, was revealed when the LC n-3 PUFAs were used at a 10-fold higher concentration [39]. Similarly, studies that rely on single time-points for measurement of response may not capture changes that occur after short-term-, or more typically after long-term treatment regimens. This point is exemplified by the early incorporation (2–14 days) of EPA, but not DHA into erythrocyte membranes, with DHA incorporation occurring later (14–28 days) [40].

Interestingly, there are instances where EPA and DHA produce opposite responses, for example in the regulation of c-abl proto-oncogene, glutathione S-transferase A1, and breast cancer type 2 susceptibility protein gene expression [41], modulation of pulse pressure in a rat model of hypertension [27], and changes to resting heart rate in healthy human subjects [42] (Table 2). These examples suggest fundamental differences in the mechanism of action for the different LC n-3 PUFAs. Discussion of factors likely to contribute to the divergent responses to individual LC n-3 PUFAs is reported in Section 3.

marinedrugs-10-02535-t002_Table 2

Summary of selected studies identifying differential effects of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and their metabolites.

Gene expression Study Summary of differences Ref.
Genes regulating inflammation, the cell cycle, apoptosis Jurkat T cells, 12.5 μM DHA (n = 3) or EPA (n = 3) for 1 day (compared to untreated cells). CD27 ligand: DHA no change, EPA ↑. Fibronectin I: DHA ↑, EPA no change. Insulin receptor: DHA ↑, EPA no change. Microsomal Glutathione S-transferase I: DHA no change, EPA ↓. Cyclin-dependent kinase 4 inhibitor 2: DHA ↑, EPA no change. Phospholipase A2: DHA ↑, EPA no change. c-abl proto-oncogene: DHA ↑, EPA ↓. Glutathione S-transferase A1: DHA ↑, EPA ↓. Breast cancer type 2 susceptibility protein: DHA ↑, EPA ↓. [41]
Cytokine mRNA expression Lipopolysaccharide-stimulated human THP-1 macrophages. 100 μM DHA (n = 5–6) or EPA (n = 5–6) for 2 days. Inhibition of TNFα, IL-1β, IL-6 mRNA: DHA > EPA. Cytoplasmic IκBα protein: DHA ↑, EPA no change. [43]
UDP-glucuronosyl transferase IAI (UGTIAI) mRNA expression Human hepatoma HepG2 cells, 50 μM DHA (n = 3) or EPA (n = 3) for 1 day (compared to vehicle). Some cells co-treated with 10 μM vitamin E. UGTIAI mRNA: DHA no change (but ↓ with vitamin E), EPA ↓ (but ↑ to control levels with vitamin E). [44]
Cannabinoid receptor 2 (CB2) and NAPE-PLD mRNA expression MC3T3-E1 osteoblast-like cells. 10 μM DHA (n = 3–4) or EPA (n = 3–4) for 3 days (compared to vehicle). CB2 mRNA: DHA no change, EPA ↓. NAPE-PLD mRNA: DHA no change, EPA ↓. [45]
PPARγ and adiponectin mRNA 3T3-L1 adipocytes. 125 μM DHA (n = 3) or EPA (n = 3) for 1 day (compared to vehicle). PPARγ mRNA: DHA ↑, EPA no change. Adiponectin mRNA: DHA ↑, EPA no change. [46]
CYP2J2 mRNA expression Human umbilical vein endothelial cells. 1, 10 μM DHA (n = 5) or EPA (n = 5) for 1 day (compared to vehicle). CYP2J2 mRNA: DHA no change, EPA ↑. [47]
Serum lipoproteins and LDL particle size Overweight, non-smoking, mildly hyperlipidemic men. DB, RD, PC. 4 g/day DHA (n = 17) or EPA (n = 19) for 6 weeks. HDL2-cholesterol: DHA ↑, EPA no change. HDL3-cholesterol: DHA no change, EPA ↓. LDL particle size: DHA ↑, EPA: no change. [48]
Serum lipoproteins Non-smoking, healthy men. DB, RD, PC. 3.6 g/day DHA (n = 72), 3.8 g/day EPA (n = 75) for 7 weeks. HDL-cholesterol: DHA ↑, EPA no change. Apolipoprotein A–I: DHA no change, EPA ↓. Total cholesterol: DHA no change, EPA ↓. Accumulation into serum phospholipids: DHA > EPA. Δ6-Desaturation activity: DHA ↓, EPA no change. Δ5-Desaturation activity: DHA ↓, EPA ↑. [49]
Serum lipoproteins Non-smoking normolipidemic men and women. B, RD. 2.3 g/day DHA (n = 25) or 2.2 g/day EPA (n = 25) for 6 weeks. HDL cholesterol: DHA ↑, EPA no change. [50]
LDL particle size Non-smoking hypertensive diabetic men and postmenopausal women. DB, RD, PC. 4 g/day DHA (n = 18) or EPA (n = 17) for 6 weeks. LDL particle size: DHA ↑, EPA no change. [51]
Triglyceride formation Rat liver microsomes. 5–20 µM DHA-CoA (n = 4) or EPA-CoA (n = 4) for 10 min. Triglyceride formation: DHA-CoA > EPA-CoA. [52]
Lipid peroxidation Rat C6 Glioblastoma cells. 100 μM DHA (n = 3) or EPA (n = 3) for 1–3 days. Thiobarbituric acid production: DHA > EPA. [53]
Endothelial cell migration Cultured H5V endothelial cells. 100 μM DHA (n = 3) or EPA (n = 3) for 24 h. Endothelial cell migration: DHA no change, EPA ↓. [54]
Enzyme activity and membrane fluidity Human cultured foreskin fibroblasts. 50 μM DHA (n = 6, membrane fluidity; n = 9 enzyme activity) or EPA (n = 6, membrane fluidity; n = 9 enzyme activity) for 4 days. 5′-nucleotidase activity: DHA ↑, EPA no change. Adenylate cyclase activity: DHA ↑, EPA no change. Fluorescence anisotropy: DHA ↑, EPA no change. [55]
Mitogen signaling pathways Jurkat T cells transfected with RasGRP. 10 μM DHA (n = 6) or EPA (n = 6) for 3 h. Potentiation of PMA-stimulated ERK1/2 activity: DHA ↑, EPA no change *. * Result likely linked to differential incorporation of the LC n-3 PUFAs into diacylglycerol and not different affinities of the phospholipids for RasGRP. [56]
Collagen-stimulated production of platelet thromboxane Non-smoking men and postmenopausal women with type 2 diabetes mellitus. DB, RD, PC. 4 g/day DHA (n = 10) or EPA (n = 11) for 6 weeks. Platelet thromboxane levels: DHA ↓, EPA no change. [57]
Platelet aggregation Healthy men and women. 1 μM DHA (n = 42) or EPA (n = 42) for 6 min. Healthy men; 1 μM DHA (n = 20) or EPA (n = 20) for 6 min (compared to ethanol control). Aggregation to collagen; men and women: EPA ↓ > DHA ↓. Aggregation to collagen; men only: EPA ↓ > DHA ↓. [29]
Platelet aggregation Human platelets. 100 μM 4(RS)-4-F4t-NeuroP or 15-F3t-IsoP for 5 min prior to U46619. Reversible aggregation to U46619: 4(RS)-4-F4t-NeuroP no change, 15-F3t-IsoP ↓. Note: 4(RS)-4-F4t-NeuroP is a product derived from DHA; 15-F3t-IsoP is a product derived from EPA. [58]
Mean platelet volume and platelet count Healthy men and women. RD, PC. 4 g/day DHA (n = 12) or EPA (n = 10) for 4 weeks. Mean platelet volume: DHA no change, EPA ↓. Platelet count: DHA no change, EPA ↑. [28]
Reactive oxygen species Goat cultured neutrophils. 25–200 μM DHA (n = 6) or EPA (n = 6) for 0.5–2 h. Cytochrome C activity in resting neutrophils: DHA ↓, EPA no change (0.5 h treatment). Cytochrome C activity in PMA-stimulated neutrophils: DHA ↓ > EPA ↓. [59]
iNOS protein expression Mouse RAW264 macrophages. 60 μM DHA (n = 3) or EPA (n = 3) for 1 day, then stimulated IFN-γ and LPS for 12 h (compared to untreated, stimulated cells). iNOS/actin protein: DHA ↓, EPA no change. [60]
Ca2+-induced opening of MPTP Cardiac mitochondria from male Wistar rats. B. 2.5% caloric intake DHA (n = 8–9) or EPA (n = 8–9). MPTP opening: DHA ↓, EPA no change. [61]
Ischaemia-induced cardiac arrhythmias (SHR) Spontaneously hypertensive rats. 0.5% w/w in the diet, up to 450 mg/kg/day; DHA (n = 10) or EPA (n = 10) for 5 weeks. Ischaemia-induced cardiac arrhythmias: DHA ↓, EPA no change. [62]
Blood pressure and thromboxane-like aortic constriction (SHR) Spontaneously hypertensive rats during the development phase of hypertension. Blood pressure: 4.5% w/w in the diet; DHA (n = 8) or EPA (n = 8) for 12 weeks. Aortic constriction: 4.5% w/w in the diet; DHA (n = 5) or EPA (n = 5) for 12 weeks. Blood pressure: DHA ↓ > EPA ↓. Aortic constriction: DHA ↓ > EPA ↓. [62]
Salt-loading induced proteinuria (SHR) Salt-loaded, stroke-prone spontaneously hypertensive rats with established hypertension. 4.5% w/w in the diet; DHA (n = 7) or EPA (n = 8) for 6, 9 and 12 weeks. Proteinuria: DHA ↓, EPA no change. [62]
Forearm blood flow (Human) Overweight, non-smoking, mildly hyperlipidemic men. DB, RD, PC. 4 g/day DHA (n = 13) or EPA (n = 13) for 6 weeks. Forearm blood flow: DHA ↑, EPA no change. Noradrenaline-mediated constriction of forearm microcirculation: DHA ↓, EPA no change. [63]
Blood pressure and Heart rate (Human) Overweight, non-smoking, mildly hyperlipidemic men. DB, RD, PC. 4 g/day DHA (n = 17) or EPA (n = 19) for 6 weeks. Mean 24 h SBP: DHA ↓, EPA no change. Mean 24 h DBP: DHA ↓, EPA no change. Mean day SBP: DHA ↓, EPA no change. Mean day DBP: DHA ↓, EPA no change. Mean 24 h HR: DBP: DHA ↓, EPA no change. Mean day HR: DBP: DHA ↓, EPA no change. Mean night HR: DBP: DHA ↓, EPA no change. [26]
Blood pressure and QT interval (male SHR) Spontaneously hypertensive rats. 240 mg/day DHA (n = 6) or EPA (n = 6) for 8 weeks compared to normal fat diet. Day SBP: DHA ↓, EPA no change. Night SBP: DHA ↓, EPA no change. Day pulse pressure: DHA ↓, EPA ↑. Night pulse pressure: DHA ↓, EPA ↑. Day QT interval: DHA ↓, EPA no change. Night QT interval: DHA ↓, EPA no change. [27]
Heart rate Non-smoking, healthy men. DB, RD, PC. 3.6 g/day DHA (n = 72) or 3.8 g/day EPA (n = 75) for 7 weeks (compared to control) Resting HR: DHA ↓, EPA ↑. [42]
Vascular tension (Rat) Pre-contracted rat isolated aorta (untreated). 1 nM–100 μM 4(RS)-4-F4t-NeuroP (n = 4) or 15-F3t-IsoP (n = 4) dose-response curves. Aortic contraction: 4(RS)-4-F4t-NeuroP no change, 15-F3t-IsoP ↑. Note: 4(RS)-4-F4t-NeuroP is a product derived from DHA; 15-F3t-IsoP is a product derived from EPA. [58]
Antidepressant effect (Human) Meta analysis, patients with depressive symptoms. DB, RD, PC. 28 studies. Treatment of depression: EPA > DHA [4]
Alzheimer disease (AD; Human) 815 subjects unaffected by AD; 65–94 years. Analysis of fish consumption using food frequency questionnaire; follow-up at 3.9 years. Risk AD: DHA ↓, EPA no change. [3]

↓, Effect of the fatty acid is to decrease; ↑, Effect of the fatty acid is to increase; B, Blinded; DB, Double-blind; RD, Randomized design; PC, Placebo controlled; SHR, spontaneously hypertensive rats; HDL, high density lipoprotein; LDL, low density lipoprotein; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid, PMA, phorbol 12-myristate 13-acetate, NAPE-PLD, N-acyl phosphatidylethanolamine-selective phospholipase D; MCP-1, monocyte chemotactic protein-1, MPTP, mitochondrial permeability transition pore.

 3. Factors Contributing to Differential Responses to EPA and DHA 3.1. Regulation of Transcription Factors

LC n-3 PUFAs regulate gene transcription by binding to a variety of nuclear receptors, including the retinoid-activated nuclear receptor, RXRβ [64] (via association with the brain fatty acid-binding protein-7 transporter [65]), and peroxisome proliferator-activated receptor (PPAR) [66,67]. In 3T3-L1 adipocytes, 125 µM DHA upregulated PPARγ mRNA expression levels while 125 µM EPA was without effect [46]. PPARγ is a transcription factor for the adiponectin gene, and activation of PPARγ leads to increased synthesis of adiponectin. DHA stimulated secretion of greater amounts of adiponectin from adipocytes than EPA, and only the DHA response was blocked by an antagonist of PPARγ [46]. The authors concluded that there may be independent actions of EPA and DHA on PPARγ/adiponectin signaling in adipocytes [46]. The selectivity of DHA over EPA for PPARγ activation may not apply to all cell types, with evidence for stimulation of PPARγ activity by both EPA and DHA in human kidney-2 (HK-2) cells [68], and by EPA in human umbilical vein endothelial cells [47]. It is possible that differential effects of the LC n-3 PUFAs may be caused by metabolism of the LC n-3 PUFA to its metabolites. A number of oxidation products of DHA were found to be more potent activators of PPARγ than DHA [69,70], although metabolites resolvin D1 and resolvin E1 were without effect [71]. It is not yet known whether EPA and metabolites of EPA have differential activity at PPAR. The contribution of LC n-3 PUFA metabolites to differential responses observed for EPA and DHA are discussed in Section 3.4.

In addition to the direct effects of EPA and DHA on transcription factors, these LC n-3 PUFAs also indirectly modulate transcription factors. For example, LC n-3 PUFAs inhibit activity of the transcription factor, nuclear factor kappa B (NFκB) by attenuating phosphorylation and degradation of the inhibitory factor, IκB-α (reported for EPA [72]), and by inhibiting the recruitment of toll-like receptor 4 to lipid rafts (reported for DHA [73]). Although 100 µM DHA was more effective than 100 µM EPA in retaining IκB-α in the cytosol of lipopolysaccharide (LPS)-stimulated macrophages, EPA and DHA were equally effective at inhibiting LPS-stimulated NFκB/DNA binding activity [43].

 3.2. Receptor-Mediated Effects of EPA and DHA

Free fatty acids were identified as endogenous ligands for the orphan G-protein coupled receptor, GPR120 following extensive ligand-binding screening [74]. GPR120 is expressed in gastrointestinal epithelial cells [74,75], and in macrophages [76], and its activation by LC n-3 PUFAs leads to secretion of glucagon-like peptide-1 from epithelial cells [74,77] and anti-inflammatory effects in macrophages [76]. Recent findings revealed short and long isoforms of GPR120, both of which were responsive to free fatty acids [78]. Although differential maximal efficacies for phosphorylation of these isoforms was reported in HEK293 cells exposed to α-linolenic acid and DHA, a comparison of EPA and DHA-mediated receptor phosphorylation was not made [78]. Nonetheless, it was speculated that the length and degree of saturation of the fatty acids may affect efficacy [78], raising the possibility that differences in efficacy might also be observed for EPA (20 carbons, 5 double bonds) and DHA (22 carbons, 6 double bonds). Whilst further studies are required to test this hypothesis, differences in amplitude of response to EPA and DHA have been reported previously. For example, serum response element-luciferase (SRE-luc) activity in HEK293 cells expressing GPR120 and the SRE-luc promoter appeared to be greater for cells treated with DHA than EPA [76]. Furthermore, secretion of glucagon-like peptide-1 from mouse colon was significantly elevated after intracolonic administration of DHA, but not EPA [77]. It is thus possible that the above interactions of EPA and DHA with GPR120 could in part explain the greater efficacy of DHA compared to EPA for the inhibition of release of pro-inflammatory cytokines from human macrophages [43] (Table 2). In that study, a single, high concentration of EPA and DHA was used (100 μM), and this was therefore likely to produce a maximal response (see [76]). Interestingly, potency does not appear to be different for EPA and DHA at GPR120. Potency of EPA and DHA for stimulation of calcium mobilization in HEK293 cells expressing GPR120, and promoter activity in HEK293 cells expressing GPR120 and SRE-luc promoter, were similar [74,76].

 3.3. Incorporation of EPA and DHA into Phospholipids

Glycerophospholipids (phospholipids) are the main component of the cell membrane, and include structures such as phosphatidylcholine and phosphatidylserine. Dietary intake of EPA and DHA increases the LC n-3 PUFA content of phospholipids with an associated reduction in arachidonic acid levels [49,79,80]. The source of LC n-3 PUFAs may affect the extent to which EPA and DHA are incorporated into phospholipids. A recent study recruited healthy, young (20–50 years) men and compared incorporation of fish oil (EPA and DHA as re-esterified triglycerides or ethyl esters, with no free fatty acids) and krill oil-derived EPA and DHA (mainly bound in phospholipids, with 21%–22% free fatty acids) into plasma phospholipids [81]. A non-significant trend for higher incorporation of EPA and DHA from krill oil was reported [81]. Although the duration of the experiment was short (24 h), the investigators were careful to match the amount of EPA and DHA that was administered for the three preparations.

To investigate possible differential incorporation of EPA and DHA into membrane phospholipids, Judé et al. [79] fed dogs a diet containing a greater amount of DHA than EPA, for 8 weeks. As expected, the plasma concentration of DHA was greater than EPA. However, despite the intake of a DHA-rich diet, EPA was preferentially incorporated into erythrocyte and cardiac membrane phospholipids. The incorporation of EPA and DHA into phospholipids was also investigated in humans receiving dietary supplementation with LC n-3 PUFAs [14,82,83]. In these studies, EPA was also more efficiently incorporated into cholesteryl esters than DHA [14], and this was ascribed to a higher efficiency of lecithin-cholesterol acyltransferase (LCAT) activity for transfer of EPA from phosphatidylcholine to cholesteryl esters [82,84]. In contrast, DHA was preferentially incorporated into triglycerides [14], with DHA serving as a preferential substrate for diacylglycerol acyltransferase [52]. Interestingly, not all studies concur with this pattern of fatty acid metabolism. The supplementation of guinea-pigs with marine oils rich in EPA led to preferential incorporation of DHA into cardiac muscle total phospholipids [85]. Whilst species differences may be responsible for the different findings, this is unlikely to occur at the level of LCAT activity since LCAT activity in guinea-pig is intermediate between that reported in dog (lower activity than in guinea pig) and human (higher activity than in guinea pig) [86].

Both EPA and DHA decrease the liberation of arachidonic acid from phospholipids by inhibiting phospholipase A2 activity [87]. Arachidonic acid is a substrate for cyclooxygenase and lipoxygenase enzymes, and the competitive reduction in arachidonic acid by EPA and DHA inhibits the generation of the 2-series prostaglandins, and 4-series leukotrienes [88,89]. As described above, EPA is a better substrate than DHA for LCAT activity [82]. The displacement of arachidonic acid by EPA in phospholipids increases cyclooxygenase-2-mediated production of PGE3, and lipoxygenase-mediated production of LTB5, from EPA, with a concomitant reduction in levels of PGE2 and LTB4[90,91,92]. The PGE2-to-PGE3 and LTB4-to-LTB5 switching described by these investigators is likely to be of clinical importance in the in vivo modulation of disease since the EPA-derived products will tend to favour anti-inflammatory, anti-mitotic and anti-allergic activities [90,91,92].

Diacylglycerol is one of the lipid molecules into which EPA and DHA can be incorporated. This molecule has a key role in cell signaling, being a potent endogenous activator of conventional and novel subclasses of protein kinase C (PKC). Diets containing LC n-3 PUFAs lead to enrichment of these fatty acids in diacylglycerol [93], primarily in the sn-2 position [94]. Judé et al. [79] showed a preferential enrichment of cardiac membrane diacylglycerol with EPA compared to DHA in dogs that were fed a fish oil diet, while Madani et al. [56] showed preferential enrichment of Jurkat T cell diacylglycerol with DHA compared to EPA. In mice fed diets rich in EPA or DHA for 10 days, isolated splenic cells showed an apparent (data for n = 2 experiments only) differential enrichment of diacylglcerol with 18:1–22:6(n-3) and 18:1–20:1(n-9) (DHA fed mice) or 18:0–18:2(n-6) (EPA fed mice) [95]. The findings show that diets containing high levels of EPA or DHA can lead to differential incorporation of fatty acids, including LC n-3 PUFAs, into diacylglycerol. The question arises as to whether this type of response might translate to differential effects on PKC signaling. This was examined in an in vitro study that compared the effects of diacylglycerol containing EPA or DHA in the sn-2 position, on PKC activity [96]. Both EPA and DHA-containing forms of diacylglycerol stimulated concentration-dependent PKCα, βI, γ, δ and ε activity, however differential responses were not observed [96]. The implication of this finding is that whilst differential incorporation of EPA and DHA into membrane phospholipids may contribute to differences in health benefits of the LC n-3 PUFAs, this is unlikely to occur at the level of diacylglycerol/ PKC signaling.

 3.4. LC <italic>n</italic>-3 PUFA Metabolites

LC n-3 PUFAs undergo enzyme-independent auto-oxidation under cell culture conditions, increasing with time and with the level of unsaturation of the fatty acid (DHA > EPA; [97]. Since oxidation products can have different activity to the parent LC n-3 PUFA, differential stability of EPA and DHA may impact on the pharmacological effect of these fatty acids. Multiple enzyme systems also convert LC n-3 PUFAs to metabolites that have biological activity [98,99] (Figure 1). The family of cytochrome P450 (CYP450) enzymes convert EPA to primary metabolites epoxyeicosatetraenoic acid (17,18-EEQ) and hydroxyeicosapentaenoic acid (20-HEPE), and DHA to epoxydocosapentaenoic acid (19,20-EDP) and hydroxydocosahexaenoic acid (22-HDoHE) [100]. Treatment of human subjects with 1.86 g EPA and 1.5 g DHA per day for 4 weeks caused a 4.7- and 2.1-fold increases in plasma levels of 17,18-EEQ and 19,20-EDP, respectively [101]. EPA is also converted to 18S- and 18R-resolvins E1 and E2 by aspirin-acetylated cyclooxygenase-2 (COX-2) and 5-lipoxygenase activity [102]. DHA is converted by aspirin-acetylated COX-2 to 17R-resolvins D1–D4 and 17R-protectin D1, and by 5- and 15-lipoxygenase to the 17S-series of these compounds [103,104,105].

Several studies have examined divergent activity EPA and DHA by studying the responses to their metabolites. Multiple isoforms of CYP450 contribute to the metabolism of EPA and DHA, and these can perform their catalytic function with different preference for the EPA and DHA substrates. For example, DHA is metabolized at a greater rate than EPA by CYP4F2, CYP4F3B, and CYP4F3A, while CYP4A11 and CYP2J2 preferentially metabolize EPA [99]. The response to the LC n-3 PUFAs will therefore be affected by expression levels of CYP450 isoforms in the tissues, as this will influence the degree to which EPA and DHA are metabolized. Importantly, the metabolites have different biological activities to each other, and to their parent LC n-3 PUFA (Figure 1). This point is exemplified by the markedly different potencies of EPA, DHA, and CYP450 metabolites of EPA and DHA for eliciting vasorelaxation. The potency of DHA for dilation of pre-constricted porcine coronary arterioles (apparent pEC50, 5.1) was ~336,000-fold lower than for its metabolite, 19,20-EDP (pEC50, 10.6) [106]. In contrast to the high potency of the DHA metabolite, the EPA metabolite 17,18-EEQ relaxed pre-constricted mouse mesenteric arteries with comparatively low potency (~pEC50, 7.0) [107].

Metabolism of arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid by cytochrome P450 (CYP450), cyclooxygenase-2 (COX-2), apirin-acetylated COX-2, and 15- and 5-lipoxygenases (LOX). Functional responses of metabolites are indicated [102,104,105,106,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123]. 20-HETE, 20-hydroxyeicosatetraenoic acid; 11,12-EET, 11,12-epoxyeicosatrienoic acid; 20-HEPE, 20-hydroxyeicosapentaenoic acid; 17,18-EEQ, 17,18-epoxyeicosatetraenoic acid; 22-HDoHE, 22-hydroxydocosahexaenoic acid; 19,20-EDP, 19,20-epoxydocosapentaenoic acid; TXA2, thromboxane A2; TXA3, thromboxane A3; PGI2, prostacyclin; PGI3, prostaglandin I3; RvE1, resolvin E1; RvD1, resolvin D1; LTB4, leukotriene B4; LTB5, leukotriene B5.

Polymorphisms in the gene encoding for the CYP450 isoforms may contribute to variation in metabolism of EPA and DHA between individuals. Several polymorphisms have been identified in the CYP1A1 gene, including a CYP1A1.2 variant (Ile462Val) that has allelic frequency up to 10% in Caucasians, and up to 33% in Asians (see [124]). This variant form of CYP1A1 metabolizes EPA to 17,18-EEQ and 19-HEPE with a 2.1 and 5.2-fold higher efficiency than the wild type enzyme [124]. The ratio of efficiency of epoxygenation to hydroxylation is also different for the variant and wild-type enzymes [124]. Since the biological activity of the metabolites can differ (see above), polymorphisms may be expected to contribute to variability in differential effects of the LC n-3 PUFAs and their metabolites between individuals.

Differential responses have also been noted for the resolvins and lipoxins; families of autacoids with anti-inflammatory and pro-resolving activities. The resolvins mediate their effects, at least in part, through the activation of G protein coupled receptors; ALX/FPR2 and GPR32 for resolvin D1 and lipoxin A4 [71,108] and ChemR23 and BLT1 for resolvin E1 [108,125]. Some similarities exist in the functional response to the autacoids and their precursor molecules. For example, both resolvin D1 and DHA induced polarization of adipose tissue-infiltrating macrophages from an M1 to an M2 phenotype, as evidenced by the attenuation of M1 markers TNF-α and IL-6 and induction of the M2 marker Arg1 [126]. However, despite these similarities, differences between the LC n-3 PUFAs and their metabolites have also been noted. Whereas resolvin D1 potently induced macrophage phagocytic activity, DHA had the opposite effect, and whereas 1 nM resolvin D1 stimulated ROS production in peritoneal macrophages, DHA was without effect even when used at a 10,000-fold higher concentration [126]. It is thus possible that some of the differential responses reported for EPA and DHA might be attributable to the extent to which they are metabolized by the different enzyme systems to their endogenous autacoid metabolites. In addition to the differences observed between the metabolites and their parent LC n-3 PUFA, differences have also been reported for anti-inflammatory and pro-resolving activity between the various metabolites. For example, 17R-resolvin D1, formed by aspirin-acetylated COX-2, was more potent than lipoxygenase-generated 17S-resolvin D1 at inhibiting leukocyte infiltration in a mouse-model of peritonitis [105]. Differential kinetics for onset of anti-inflammatory and pro-resolving activity for the metabolites of arachidonic acid, EPA and DHA may contribute to some of the differential responses reported for these mediators. A stable analogue of 15-epi-lipoxin A4 inhibited pro-inflammatory cytokine production in a mouse-model of peritonitis, 4 h after administration [127]. At this time-point, resolvin E1 was without effect, however when assessed 12 h post-administration, it inhibited pro-inflammatory cytokine production with magnitude equal to, or greater than that observed for the lipoxin [127]. Few studies have examined the biological activities of the CYP450 metabolites, and further research into this area is warranted.

 4. Conclusions

Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been recommended for management of patients with wide-ranging chronic diseases, including coronary heart disease, rheumatoid arthritis, dementia, and depression. Although there is much evidence supporting uniformity of response to the individual LC n-3 PUFAs, there are also a plethora of studies that have shown qualitative and quantitative differences in response to EPA and DHA. In this review, we have explored some of the reasons for these differences. We propose that there are multiple factors that contribute to the differential effects of EPA and DHA, including differences in direct and indirect activation of transcription factors, impact of length, degree of saturation and stability of the fatty acid on efficacy, and differential efficiency for incorporation of the fatty acids into phospholipids. In addition, potency of the metabolites of EPA and DHA are often markedly different to the parent LC n-3 PUFA, and divergence in efficiency of enzymes to metabolize EPA and DHA can contribute to observed diversity in cellular response. We suggest that with improved understanding of the similarities and differences for EPA and DHA, an opportunity exists to customize recommendations for intake of EPA or DHA that can be tailored to the patient’s condition.

Samples Availability: Available from the authors.

 References Fortin P.R. Lew R.A. Liang M.H. Wright E.A. Beckett L.A. Chalmers T.C. Sperling R.I. Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis J. Clin. Epidemiol. 1995 48 1379 1390 10.1016/0895-4356(95)00028-3 Geleijnse J.M. Giltay E.J. Grobbee D.E. Donders A.R.T. Kok F.J. Blood pressure response to fish oil supplementation: Metaregression analysis of randomized trials J. Hypertens. 2002 20 1493 1499 10.1097/00004872-200208000-00010 Morris M.C. Evans D.A. Bienias J.L. Tangney C.C. Bennett D.A. Wilson R.S. Aggarwal N. Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer Disease Arch. Neurol. 2003 60 940 946 10.1001/archneur.60.7.940 Martins J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: Evidence from a meta-analysis of randomized controlled trials J. Am. Coll. Nutr. 2009 28 525 542 20439549 Kwak S.M. Myung S.-K. Lee Y.J. Seo H.G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease. A meta-analysis of randomized, double-blind, placebo-controlled trials Arch. Intern. Med. 2012 172 686 694 10.1001/archinternmed.2012.262 Rizos E.C. Nitzani E.E. Bika E. Kostapanos M.S. Elisaf M.S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis JAMA 2012 308 1024 1033 10.1001/2012.jama.11374 Burr M.L. Fehily A.M. Gilbert J.F. Rogers S. Holliday R.M. Sweetnam P.M. Elwood P.C. Deadman N.M. Effects of changes in fat, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART) Lancet 1989 2 757 761 2571009 GISSI-Prevenzione Investigators Dietary supplemenatation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial Lancet 1999 354 447 455 10.1016/S0140-6736(99)07072-5 Kromhout D. Omega-3 fatty acids and coronary heart disease. The final verdict? Curr. Opin. Lipidol. 2012 23 10.1097/MOL.0b013e328359515f Laufs U. Schirmer S.H. Margarines supplemented with low dose n-3 fatty acids are not effective in secondary prevention Eur. Heart J. 2012 33 1555 1557 10.1093/eurheartj/ehs063 O’Sullivan T.A. Ambrosini G. Beilin L.J. Mori T.A. Oddy W.H. Dietary intake and food sources of fatty acids in Australian adolescents Nutrition 2011 27 153 159 10.1016/j.nut.2009.11.019 Gibson R.A. Neumann M.A. Lien E.L. Boyd K.A. Tu W.C. Docosahexaenoic acid synthesis from alpha-linolenic acid is inhibited by diets high in polyunsaturated fatty acids Prostaglandins Leukot. Essent. Fatty Acids 2012 Burdge G.C. Finnegan Y.E. Minihane A.M. Williams C.M. Wootton S.A. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]α-linolenic acid to longer-chain fatty acids and partitioning towards β-oxidation in older men Br. J. Nutr. 2003 90 311 321 10.1079/BJN2003901 Singer P. Berger I. Wirth M. Gödicke W. Jaeger W. Voigt S. Slow desaturation and elongation of linoleic and α-linolenic acids as a rationale of eicosapentaenoic acid-rich diet to lower blood pressure and serum lipids in normal, hypertensive and hyperlipidemic subjects Prostaglandins Leukot. Med. 1986 24 173 193 10.1016/0262-1746(86)90125-3 Block R.C. Harris W.S. Pottala J.V. Determinants of blood cell omega-3 fatty acid content Open Biomark. J. 2008 1 1 6 10.2174/1875318300801010001 Astorg P. Arnault N. Czernichow S. Noisette N. Galan P. Hercberg S. Dietary intakes and food sources of n- and n-3 PUFA in French adult men and women Lipids 2004 39 527 535 10.1007/s11745-004-1259-6 Howe P. Meyer B. Record S. Baghurst K. Dietary intake of long-chain ω-3 polyunsaturated fatty acids: Contribution of meat sources Nutrition 2006 22 47 53 10.1016/j.nut.2005.05.009 Yamagishi K. Iso H. Date C. Fukui M. Wakai K. Kikuchi S. Inaba Y. Tanabe N. Tamakoshi A. Fish, ω-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women J. Am. Coll. Cardiol. 2008 52 988 996 10.1016/j.jacc.2008.06.018 Scientific Advisory Committee on Nutrition Advice on Fish Consumption: Benefits & Risks (accessed on 5 September 2012) Available online:http://www.sacn.gov.uk/pdfs/fics_sacn_advice_fish.pdf French Agency for Food Environmental and Occupational Health & Safety Opinion of the French Food Safety Agency Regarding the Benefits/Risks of Fish Consumption (accessed on 5 September 2012) Available online:http://www.anses.fr/Documents/NUT2008sa0123EN.pdf Health Council of the Netherlands Guidelines for a Healthy Diet (accessed on 5 September 2012) Available online:http://www.gezondheidsraad.nl/en/publications/guidelines-healthy-diet-2006-0 Heart Foundation of Australia Position Statement, 2008: Fish, Fish Oils, n-3 Polyunsaturated Fatty Acids and Cardiovascular Health (accessed on 5 September 2012) Available online:http://www.heartfoundation.org.au/ SiteCollection Documents/Fish-position-statement.pdf Freeman M.P. Hibbeln J.R. Wisner K.L. Davis J.M. Mischoulon D. Peet M. Keck P.E. Marangell L.B. Richardson A.J. Lake J. Stoll A.L. Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry J. Clin. Psychiatry 2006 67 1954 1967 10.4088/JCP.v67n1217 McNamara R.K. Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: Current status, future direction, and dietary recommendations Prostaglandins Leukot. Essent. Fatty Acids 2009 81 223 231 10.1016/j.plefa.2009.05.017 Sumich A. Matsudaira T. Gow R.V. Ibrahimovic A. Ghebremeskel K. Crawford M. Taylor E. Resting state electroencephalographic correlates with red cell long-chain fatty acids, memory performance and age in adolescent boys with attention deficit disorder Neuropharmacology 2009 57 708 714 10.1016/j.neuropharm.2009.07.024 Mori T.A. Bao D.Q. Burke V. Puddey I.B. Beilin L.J. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans Hypertension 1999 34 253 260 10.1161/01.HYP.34.2.253 Rousseau-Ralliard D. Moreau D. Guilland J.-C. Raederstorff D. Grynberg A. Docosahexaenoic acid, but not eicosapentaenoic acid, lowers ambulatory blood pressure and shortens interval QT in spontaneously hypertensive rats in vivo Prostaglandins Leukot. Essent. Fatty Acids 2009 80 269 277 10.1016/j.plefa.2009.03.003 Park Y. Harris W. EPA, but not DHA, decreases mean platelet volume in normal subjects Lipids 2002 37 941 946 10.1007/s11745-006-0984-1 Phang M. Garg M.L. Sinclair A.J. Inhibition of platelet aggregation by omega-3 polyunsaturated fatty acids is gender specific-Redefining platelet response to fish oils Prostaglandins Leukot. Essent. Fatty Acids 2009 81 35 40 10.1016/j.plefa.2009.05.001 Hamilton K. Brooks P. Holmes M. Cunningham J. Russell F.D. Evaluation of the composition of omega-3 fatty acids in dietary oil supplements Nutr. Diet. 2010 67 182 189 10.1111/j.1747-0080.2010.01453.x Phang M. Sinclair A.J. Lincz L.F. Garg M.L. Gender-specific inhibition of platelet aggregation following omega-3 fatty acid supplementation Nutr. Metab. Cardiovasc. Dis. 2012 22 109 114 10.1016/j.numecd.2010.04.012 Salunkhe D. Tiwari N. Walujkar S. Bhadekar R. Halomonas sp. nov., an EPA-producing mesophilic marine isolate from the Indian Ocean Pol. J. Microbiol. 2011 60 73 78 21630577 Soltan S.S.A.M. Gibson R.A. Levels of omega 3 fatty acids in Australian seafood Asia Pac. J. Clin. Nutr. 2008 17 385 390 18818157 Kris-Etherton P.M. Harris W.S. Appel L.J. Omega-3 fatty acids and cardiovascular disease. New recommendations from the American Heart Association Arterioscler. Thromb. Vasc. Biol. 2003 23 151 152 10.1161/01.ATV.0000057393.97337.AE World Health Organisation Population Nutrient Intake Goals for Preventing Diet-Related Chronic Diseases (accessed on 5 September 2012) Available online:http://www.who.int/nutrition/topics/5_population_nutrient/en/index13.html Nutrient Reference Values for Australia and New Zealand (accessed on 5 September 2012) Available online:http://www.nrv.gov.au/resources/_files/n35-fat.pdf Cancer Council of Australia Position Statement, 2009: Omega-3 Fatty Acids, Fish and Cancer Prevention (accessed on 5 September 2012) Available online:http://www.cancercouncil.com.au/wp-content/uploads/2010/09/Fish-Omega3-Fatty-Acids-and-Cancer-Position-Statement.pdf International Society for the Study of Fatty Acids and Lipids Intake of PUFA in Health Adults (accessed on 5 September 2012) Available online:http://www.issfal.org/statements/pufa-recommendations/statement-3 Yusufi A.N.K. Cheng J. Thompson M.A. Walker H.J. Gray C.E. Warner G.M. Grande J.P. Differential effects of low-dose docosahexaenoic acid and eicosapentaenoic acid on the regulation of mitogenic signalling pathways in mesangial cells J. Lab. Clin. Med. 2003 141 318 330 10.1016/S0022-2143(03)00005-2 Owen A.J. Peter-Przyborowska B.A. Hoy A.J. McLennan P.L. Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition Lipids 2004 39 955 961 10.1007/s11745-004-1317-0 Verlengia R. Gorjão R. Kanunfre C.C. Bordin S. de Lima T.M. Martins E.F. Curi R. Comparative effects of eicosapentaenoic acid and docosahexaenoic acid on proliferation, cytokine production, and pleiotropic gene expression in Jurkat cells J. Nutr. Biochem. 2004 15 657 665 10.1016/j.jnutbio.2004.04.008 Grimsgaard S. Bønaa K.H. Hansen J.-B. Myhre E.S.P. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans Am. J. Clin. Nutr. 1998 68 52 59 9665096 Weldon S.M. Mullen A.C. Loscher C.E. Hurley L.A. Roche H.M. Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid J. Nutr. Biochem. 2007 18 250 258 10.1016/j.jnutbio.2006.04.003 Caputo M. Zirpoli H. Torino G. Tecce M.F. Selective regulation of UGT1A1 and SREBP-1c mRNA expression by docosahexaenoic, eicosapentaenoic, and arachidonic acids J. Cell. Physiol. 2010 226 187 193 Hutchins H.L. Li Y. Hannon K. Watkins B.A. Eicosapentaenoic acid decreases expression of anandamide synthesis enzyme and cannabinoid receptor 2 in osteoblast-like cells J. Nutr. Biochem. 2011 22 195 200 10.1016/j.jnutbio.2010.06.001 Oster R.T. Tishinsky J.M. Yuan Z. Robinson L.E. Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPARγ mRNA, in 3T3-L1 adipocytes Appl. Physiol. Nutr. Metab. 2010 35 783 789 10.1139/H10-076 Wang D. Hirase T. Nitto T. Soma M. Node K. Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor γ in endothelial cells J. Cardiol. 2009 54 368 374 10.1016/j.jjcc.2009.06.004 Mori T.A. Burke V. Puddey I.B. Watts G.F. O’Neal D.N. Best J.D. Beilin L.J. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men Am. J. Clin. Nutr. 2000 71 1085 1094 10799369 Grimsgaard S. Bønaa K.H. Hansen J.-B. Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids Am. J. Clin. Nutr. 1997 66 649 659 9280188 Egert S. Kannenberg F. Somoza V. Erbersdobler H.F. Wahrburg U. Dietary α-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans J. Nutr. 2009 139 861 868 10.3945/jn.108.103861 Woodman R.J. Mori T.A. Burke V. Puddey I.B. Watts G.F. Best J.D. Beilin L.J. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients Diabetes Care 2003 26 253 10.2337/diacare.26.1.253 Madsen L. Rustan A.C. Vaagenes H. Berge K. Dyrøy E. Berge R.K. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference Lipids 1999 34 951 963 10.1007/s11745-999-0445-x Leonardi F. Attorri L. di Benedetto R. di Biase A. Sanchez M. Nardini M. Salvati S. Effect of arachidonic, eicosapentaenoic and docosahexaenoic acids on the oxidative status of C6 glioma cells Free Radic. Res. 2005 39 865 874 10.1080/10715760500145069 Tonutti L. Manzi L. Tacconi M.T. Bazzoni G. Eicosapentaenoic acid inhibits endothelial cells migration in vitro J. Angiogenesis Res. 2010 2 12 10.1186/2040-2384-2-12 Brown E.R. Subbaiah P.V. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on human skin fibroblasts Lipids 1994 29 825 829 10.1007/BF02536249 Madani S. Hichami A. Charkaoui-Malki M. Khan N.A. Diacylglycerols containing omega 3 and omega 6 fatty acids bind to RasGRP and modulate MAP kinase activation J. Biol. Chem. 2004 279 1176 1183 14583629 Woodman R.J. Mori T.A. Burke V. Puddey I.B. Barden A. Watts G.F. Beilin L.J. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients Atherosclerosis 2003 166 85 93 10.1016/S0021-9150(02)00307-6 Barden A. Mas E. Henry P. Durand T. Galano J.M. Roberts L.J. Croft K.D. Mori T.A. The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function Free Radic. Res. 2011 45 469 476 10.3109/10715762.2010.544730 Pisani L.F. Lecchi C. Invernizzi G. Sartorelli P. Savoini G. Ceciliani F. In vitro modulatory effect of ω-3 polyunsaturated fatty acid (EPA and DHA) on phagocytosis and ROS production of goat neutrophils Vet. Immunol. Immunopathol. 2009 131 79 85 10.1016/j.vetimm.2009.03.018 Komatsu W. Ishihara K. Murata M. Saito H. Shinohara K. Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-γ plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress Free Radic. Biol. Med. 2003 34 1006 1016 10.1016/S0891-5849(03)00027-3 Khairallah R.J. Sparagna G.C. Khanna N. O’Shea K.M. Hecker P.A. Kristian T. Fiskum G. des Rosiers C. Polster B.M. Stanley W.C. Dietary supplementation with docosahexaenoic acid, but not eicosapentaenoic acid, dramatically alters cardiac mitochondrial phospholipid fatty acid composition and prevents permeability transition Biochim. Biophys. Acta 2010 1797 1555 1562 10.1016/j.bbabio.2010.05.007 McLennan P. Howe P. Abeywardena M. Muggli R. Raederstorff D. Mano M. Rayner T. Head R. The cardiovascular protective role of docosahexaenoic acid Eur. J. Pharmacol. 1996 300 83 89 10.1016/0014-2999(95)00861-6 Mori T.A. Watts G.F. Burke V. Hilme E. Puddey I.B. Beilin L.J. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men Circulation 2000 102 1264 1269 10.1161/01.CIR.102.11.1264 Liu R.-Z. Graham K. Clubrecht D.D. Lai R. Mackey J. Godbout R. A fatty acid-binding protein 7/RXRβ pathway enhances survival and proliferation in triple-negative breast cancer J. Pathol. 2012 228 310 321 10.1002/path.4001 Balendiran G.K. Schnütgen F. Scapin G. Börchers T. Xhong N. Lim K. Godbout R. Spener F. Sacchettini J.C. Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein J. Biol. Chem. 2000 275 27045 27054 10854433 Edwards I.J. O’Flaherty J.T. Omega-3 fatty acids and PPARγ in cancer PPAR Res. 2008 2008 358052 18769551 Comba A. Lin Y.-H. Eynard A.R. Valentich M.A. Fernandez-Zapico M.E. Pasqualini M.E. Basic aspects of tumor cell fatty acid-regulated signalling and transcription factors Cancer Metastasis Rev. 2011 30 325 342 10.1007/s10555-011-9308-x Li H. Ruan X.Z. Powis S.H. Fernando R. Mon W.Y. Wheeler D.C. Moorhead J.F. Varghese Z. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: Evidence for a PPAR-γ-dependent mechanism Kidney Int. 2005 67 867 874 10.1111/j.1523-1755.2005.00151.x Yamamoto K. Itoh T. Abe D. Shimizu M. Kanda T. Koyama T. Nishikawa M. Tamai T. Ooizumi H. Yamada S. Identification of putative metabolites of docosahexaenoic acid as potent PPARγ agonists and antidiabetic agents Bioorg. Med. Chem. Lett. 2005 15 517 522 10.1016/j.bmcl.2004.11.05315664804 Itoh T. Yamamoto K. Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand Naunyn Schmiedeberg Arch. Pharmacol. 2008 377 541 547 10.1007/s00210-007-0251-x Krishnamoorthy S. Recchiuti A. Chiang N. Yacoubian S. Lee C.-H. Yang R. Petasis N. Serhan C.N. Resolvin D1 binds human phagocytes with evidence for proresolving receptors Proc. Natl. Acad. Sci. USA 2010 107 1660 1665 10.1073/pnas.090734210720080636 Zhao Y. Joshi-Barve S. Barve S. Chen L.H. Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κB activation J. Am. Coll. Nutr. 2004 23 71 78 14963056 Wong S.W. Kwon M.-J. Choi A.M.K. Kim H.-P. Nakahira K. Hwang D.H. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner J. Biol. Chem. 2009 284 27384 27392 10.1074/jbc.M109.04406519648648 Hirasawa A. Tsumaya K. Awaji T. Katsuma S. Adachi T. Yamada M. Sugimoto Y. Miyazaki S. Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 Nat. Med. 2005 11 90 94 10.1038/nm1168 Miyauchi S. Hirasawa A. Iga T. Liu N. Itsubo C. Sadakane K. Hara T. Tsujimoto G. Distribution and regulation of protein expression of the free fatty acid receptor GPR120 Naunyn Schmiedeberg Arch. Pharmacol. 2009 379 427 434 10.1007/s00210-008-0390-8 Oh D.Y. Talukdar S. Bae E.J. Imamura T. Morinaga H. Fan W.Q. Li P. Lu W.J. Watkins S.M. Olefsky J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects Cell 2010 142 687 698 10.1016/j.cell.2010.07.041 Morishita M. Tanak T. Shida T. Takayama K. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion J. Control. Release 2008 132 99 104 10.1016/j.jconrel.2008.09.001 Burns R.N. Moniri N.H. Agonism with the omega-3 fatty acids α-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor Biochem. Biophys. Res. Commun. 2010 396 1030 1035 10.1016/j.bbrc.2010.05.057 Judé S. Martel E. Vincent F. Besson P. Couet C. Ogilvie G.K. Pinault M. de Chalendar C. Bougnoux P. Richard S. Dietary long-chain n-3 fatty acids modify blood and cardiac phospholipids and reduce protein kinase-C-δ and protein kinase-C-ε translocation Br. J. Nutr. 2007 98 1143 1151 17663802 O’Shea K.M. Khairallah R.J. Sparagna G.C. Xu W. Hecker P.A. Robillard-Frayne I. des Rosiers C. Kristian T. Murphy R.C. Fiskum G. Dietary ω-3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca2+-induced permeability transition J. Mol. Cell. Cardiol. 2009 47 819 827 10.1016/j.yjmcc.2009.08.014 Schuchardt J.P. Schneider I. Meyer H. Neubronner J. von Schacky C. Hahn A. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations-A comparative bioavailability study of fish oil vs. krill oil Lipids Health Dis. 2011 10 145 10.1186/1476-511X-10-145 Holub B.J. Bakker D.J. Skeaff C.M. Alterations in molecular species of cholesterol esters formed via plasma lecithin-cholesterol acyltransferase in human subjects consuming fish oil Atherosclerosis 1987 66 11 18 10.1016/0021-9150(87)90174-23632742 Subbaiah P.V. Kaufman D. Bagdade J.D. Incorporation of dietary n-3 fatty acids into molecular species of phosphatidyl choline and cholesteryl ester in normal human plasma Am. J. Clin. Nutr. 1993 58 360 380 8237847 Parks J.S. Thuren T.Y. Schmitt J.D. Inhibition of lecithin:Cholesterol acyltransferase activity by synthetic phosphatidylcholine species containing eicosapentaenoic acid or docosahexaenoic acid in the sn-2 position J. Lipid Res. 1992 33 879 887 1387413 Murphy M.G. Wright V. Ackman R.G. Horackova M. Diets enriched in menhaden fish oil, seal oil, or shark liver oil have distinct effects on the lipid and fatty-acid composition of guinea pig heart Mol. Cell. Biochem. 1997 177 257 269 10.1023/A:1006871524271 Ha Y.C. Barter P.J. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species Comp. Biochem. Physiol. 1982 71B 265 269 Shikano M. Masuzawa Y. Yazawa K. Takayama K. Kudo I. Inoue K. Complete discrimination of docosahexaenoate from arachidonate by 85 kDa cytosolic phospholipase A2 during the hydrolysis of diacyl- and alkenylacylglycerophosphoethanolamine Biochim. Biophys. Acta 1994 1212 211 216 10.1016/0005-2760(94)90255-0 Chaudry A.A. Wahle K.W. McClinton S. Moffat L.E. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: Effects of fatty acids and cyclooxygenase inhibitors Int. J. Cancer 1994 57 176 180 10.1002/ijc.2910570208 Raederstorff D. Pantze M. Bachmann H. Moser U. Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation Int. Arch. Allergy Immunol. 1996 111 284 290 10.1159/000237379 Payan D.G. Wong M.Y. Chernov-Rogan T. Valone F.H. Pickett W.C. Blake V.A. Gold W.M. Goetzl E.J. Alterations in human leukocyte function induced by ingestion of eicosapentaenoic acid J. Clin. Immunol. 1986 6 402 410 10.1007/BF00915380 Hung P. Kaku S. Yunoki S. Ohkura K. Gu J.-Y. Ikeda I. Sugano M. Yazawa K. Yamada K. Dietary effect of EPA-rich and DHA-rich fish oils on the immune function of Sprague-Dawley rats Biosci. Biotechnol. Bochem. 1999 63 135 140 10.1271/bbb.63.135 Hawcroft G. Loadman P.M. Belluzzi A. Hull M.A. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signalling in human colorectal cancer cells Neoplasia 2010 12 618 627 20689756 Pehowich D.J. Dietary n-3 fatty acids alter angiotensin-induced contraction and 1,2-diacylglycerol fatty acid composition in thoracic aortas from diabetic rats Prostaglandins Leukot. Essent. Fatty Acids 1998 58 301 309 10.1016/S0952-3278(98)90040-0 Hichami A. Morin C. Rousseau E. Khan N.A. Diacylglycerol-containing docosahexaenoic acid in acyl chain modulates airway smooth muscle tone Am. J. Respir. Cell Mol. Biol. 2005 33 378 386 10.1165/rcmb.2005-0136OC Fowler K.H. McMurray D.N. Fan Y.-Y. Aukema H.M. Chapkin R.S. Purified dietary n-3 polyunsaturated fatty acids alter diacylglycerol mass and molecular species composition in concanavalin A-stimulated murine splenocytes Biochim. Biophys. Acta 1210 1993 89 96 10.1016/0005-2760(93)90053-C8257724 Madani S. Hichami A. Legrand A. Belleville J. Khan N.A. Implication of acyl chain of diacylglycerols in activation of different isoforms of protein kinase C FASEB J. 2001 15 2595 2601 10.1096/fj.01-0753int Maddipati K.R. Zhou S.-L. Stability and analysis of eicosanoids and docosanoids in tissue culture media Prostaglandins Other Lipid Mediat. 2011 94 59 72 10.1016/j.prostaglandins.2011.01.003 Harmon S.D. Fang X. Kaduce T.L. Hu S. Gopal V.R. Falck J.R. Spector A.A. Oxygenation of ω-3 fatty acids by human cytochrome P450 4F3B: Effect on 20-hydroxyeicosatetraenoic acid production Prostaglandins Leukot. Essent. Fatty Acids 2006 75 169 177 10.1016/j.plefa.2006.05.005 Arnold C. Markovic M. Blossey K. Wallukat G. Fischer R. Dechend R. Konkel A. von Schacky C. Luft F.C. Muller D.N. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids J. Biol. Chem. 2010 285 32720 32733 10.1074/jbc.M110.11840620732876 Konkel A. Schunck W.-H. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids Biochim. Biophys. Acta 1814 2011 210 222 10.1016/j.bbapap.2010.09.00920869469 Shearer G.C. Harris W.S. Pedersen T.L. Newman J.W. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters J. Lipid Res. 2010 51 2074 2081 10.1194/M900193-JLR200 Oh S.F. Pillai P.S. Recchiuti A. Yang R. Serhan C.N. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation J. Clin. Invest. 2011 121 569 581 10.1172/JCI42545 Serhan C.N. Hong S. Gronert K. Colgan S.P. Devchand P.R. Mirick G. Moussignac R.-L. A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals J. Exp. Med. 2002 196 1025 1037 10.1084/jem.20020760 Hong S. Gronert K. Devchand P.R. Moussignac R.-L. Serhan C.N. Novel Docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells J. Biol. Chem. 2003 278 14677 14687 10.1074/jbc.M30021820012590139 Sun Y.-P. Oh S.F. Uddin J. Yang R. Gotlinger K. Campbell E. Colgan S.P. Petasis N.A. Serhan C.N. Resolvin D1 and its aspirin-triggered 17R epimer: Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation J. Biol. Chem. 2007 282 9323 9334 10.1074/jbc.M60921220017244615 Ye D. Zhang D. Oltman C. Dellsperger K. Lee H.-C. Vanrollins M. Cytochrome P-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels J. Pharmacol. Exp. Ther. 2002 303 768 776 10.1124/jpet.303.2.768 Hercule H.C. Salanova B. Essin K. Honeck H. Falck J.R. Sausbier M. Ruth P. Schunck W.-H. Luft F.C. Gollasch M. The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BKα channel subunit in rodents Exp. Physiol. 2007 92 1067 1076 10.1113/expphysiol.2007.038166 Fredman G. Serhan C.N. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution Biochem. J. 2011 437 185 197 10.1042/BJ20110327 Wang J.-S. Singh H. Zhang F. Ishizuka T. Deng H. Kemp R. Wolin M.S. Hintze T.H. Abraham N.G. Nasjletti A. Laniado-Schwartzman M. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus Circ. Res. 2006 98 962 969 10.1161/01.RES.0000217283.98806.a6 Cheng J. Ou J.-S. Singh H. Falxk J.R. Narsimhaswany D. Pritchard K.A. Laniado-Schwartzman M. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling Am. J. Physiol. Heart Circ. Physiol. 2008 294 H1018 H1026 10.1152/ajpheart.01172.2007 Campbell W.B. Gebremedhin D. Pratt P.F. Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors Circ. Res. 1996 78 415 423 10.1161/01.RES.78.3.415 Fisslthaler B. Popp R. Kiss L. Potente M. Harder D.R. Fleming I. Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries Nature 1999 401 493 497 10.1038/46816 Wada M. DeLong C.J. Hong Y.H. Rieke C.J. Song I. Sidhu R.S. Yuan C. Warnock M. Schmaier A.H. Yokoyama C. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived substrates and products J. Biol. Chem. 2007 282 22254 22266 10.1074/jbc.M70316920017519235 Needleman P. Raz A. Minkes M.S. Ferrendelli J.A. Sprecher H. Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties Proc. Natl. Acad. Sci. USA 1979 76 944 948 10.1073/pnas.76.2.944 Takano T. Clish C.B. Gronert K. Petasis N. Serhan C.N. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues J. Clin. Invest. 1998 101 819 826 10.1172/JCI1578 Lee T.H. Mencia-Huerta J.-M. Shih C. Corey E.J. Lewis R.A. Austen K.F. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product J. Biol. Chem. 1984 259 2383 2389 6321468 Goldman D.W. Pickett W.C. Goetzl E.J. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid Biochem. Biophys. Res. Commun. 1983 117 282 288 10.1016/0006-291X(83)91572-3 Serhan C.N. Hamberg M. Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes Proc. Natl. Acad. Sci. USA 1984 81 5335 5339 10.1073/pnas.81.17.5335 Serhan C.N. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution Histochem. Cell Biol. 2004 122 305 321 10.1007/s00418-004-0695-8 Morin C. Sirois M. Echave V. Rizcallah E. Rousseau E. Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung Am. J. Physiol. Lung Cell Mol. Physiol. 2009 296 L130 L139 18978038 Tjonahen E. Oh S.F. Siegelman J. Elangovan S. Percarpio K.B. Hong S. Arita M. Serhan C.N. Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis Chem. Biol. 2006 13 1193 1202 10.1016/j.chembiol.2006.09.011 Serhan C.N. Fredman G. Yang R. Karamnov S. Belayev L.S. Bazan N.G. Zhu M. Winkler J.W. Petasis N.A. Novel proresolving aspirin-triggered DHA pathway Chem. Biol. 2011 18 976 987 10.1016/j.chembiol.2011.06.008 Serhan C.N. Gotlinger K. Hong S. Lu Y. Siegelman J. Baer T. Yang R. Colgan S.P. Petasis N.A. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: Assignments of dihydroxy-containing docosatrienes J. Immunol. 2006 176 1848 1859 16424216 Schwarz D. Kisselev P. Chernogolov A. Schunck W.-H. Roots I. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns Biochem. Biophys. Res. Commun. 2005 336 779 783 10.1016/j.bbrc.2005.08.172 Arita M. Ohira T. Sun Y.-P. Elangovan S. Chiang N. Serhan C.N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation J. Immunol. 2007 178 3912 3917 17339491 Titos E. Rius B. González-Périz A. López-Vicario C. Morán-Salvador E. Martínez-Clemente M. Arroyo V. Clária J. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype J. Immunol. 2011 187 5408 5418 10.4049/jimmunol.1100225 Bannenberg G.L. Chiang N. Ariel A. Arita M. Tjonahen E. Gotlinger K.H. Hong S. Serhan C.N. Molecular circuits of resolution: Formation and actions of resolvins and protectins J. Immunol. 2005 174 4345 4355 15778399